$CGIX News
Last published 5y ago
- 5y agoCGIXCancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business DevelopmentGlobeNewswireRUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of...
- 5y agoCGIXCancer Genetics to Present at the Annual 33rd ROTH ConferenceGlobeNewswireRUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
- 5y agoCGIXCancer Genetics to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireRUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
- 5y agoCGIXCancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireRUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 5y agoCGIXCancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireRUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 5y agoCGIXCancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-MarketGlobeNewswireRUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 5y agoCGIXConcordance Between Buccal Cavity Swab and Nasopharyngeal Swab for Detection of SARS-CoV-2 Via RT-PCR and ELISA - NCT04732637ClinicalTrials.govConcordance between buccal cavity swab and contemporary nasal swab.
- 5y agoCGIXCancer Genetics Announces $10.0 Million Private Placement Priced At-the-MarketGlobeNewswireRUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 5y agoCGIXCancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. WainwrightGlobeNewswireRUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
- 5y agoCGIXAKERTGCDNKNMoore Kuehn Encourages CGIX, AKER, TGC and DNKN Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoCGIXCancer Genetics Reports Third Quarter 2020 Financial ResultsGlobeNewswireRUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
- 6y agoCGIXStemoniX Announces Publication Demonstrating High-throughput Screening Using Human-derived CNS ModelsACCESS Newswire, Inc. announced the publication of a new research paper, "," in the journal . The research describes how the StemoniX microBrain 3D platform can be used in functional high-throughput screens to identify potentially new therapeutics for central nervous system (CNS) indications.
- 6y agoCXOCGIXCBMGRESIMoore Kuehn Encourages CGIX, CXO, CBMG, and RESI Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
- 6y agoCGIXCancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional SharesGlobeNewswireRutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
- 6y agoCGIXCancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 MillionGlobeNewswireRutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services,...
- 6y agoCGIXCancer Genetics, Inc. Announces $2.0 Million Bought Deal OfferingGlobeNewswireRutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services,...
- 6y agoCGIXStemoniX Announces Addition to Board of DirectorsACCESS NewswireCompany Announces Appointment of John Fletcher
- 6y agoBDGECGIXCBMGBMCHMoore Kuehn Encourages BDGE, CBMG, CGIX, and BMCH Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoCGIXCancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment ConferenceGlobeNewswireRUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 6y agoCGIXCancer Genetics and StemoniX Announce Joint Proof-of-Concept ProgramGlobeNewswireRUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and...
- 6y agoDCOMMXIMCGIXPTIMoore Kuehn Encourages MXIM, CGIX, PTI, and DCOM Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
- 6y agoCGIXCancer Genetics and StemoniX Sign Definitive Agreement to MergeGlobeNewswireCombined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the...
- 6y agoCGIXCancer Genetics Reports Second Quarter 2020 Financial ResultsGlobeNewswireRUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
- 6y agoCGIXCancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business UpdatesGlobeNewswireRUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
- 6y agoCGIXCancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business UpdatesGlobeNewswireRUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...
- 6y agoCGIXCancer Genetics Issues Letter to ShareholdersGlobeNewswireRUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
- 7y agoCGIXIDXGCancer Genetics, Inc. Announces Strategic TransactionsGlobeNewswireNote Payment Received from Interpace Diagnostics Group, Inc. Settlement Agreement with NovellusDx Restructured Note Agreement with Unsecured Lender M&A Advisory Agreement with H.C....
- 8y agoCGIXCancer Genetics, Inc. (CGIX) CEO John Roberts on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoCGIXCancer Genetics' (CGIX) CEO Jay Roberts on Q1 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoCGIXCancer Genetics' (CGIX) Management on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoCGIXCancer Genetics' (CGIX) CEO Panna Sharma on Acquisition of vivoPharm Conference Call (Transcript)Earnings Call Transcripts
- 10y agoCGIXCancer Genetics' (CGIX) CEO Panna Sharma on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts